116 related articles for article (PubMed ID: 24266997)
1. [The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis].
Chen YP; Wang W; Wang ZK; Wei DN; Zhang J
Zhonghua Nei Ke Za Zhi; 2013 Jul; 52(7):567-9. PubMed ID: 24266997
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
6. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
8. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Wakata N; Saito T; Tanaka S; Hirano T; Oka K
Clin Neurol Neurosurg; 2003 Dec; 106(1):5-8. PubMed ID: 14643908
[TBL] [Abstract][Full Text] [Related]
11. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
12. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Ahn SW; Joo IS; Kim BJ; Sung JJ; Kang SY; Oh J; Minn YK; Suh BC; Oh SY; Hong YH; Nam TS; Seok JI; Park YE; Shin HY; Cho EB; Shin JY; Seok HY; Park JS; Min JH; Seok JM; Kim BJ
J Neurol Sci; 2017 Aug; 379():271-275. PubMed ID: 28716258
[TBL] [Abstract][Full Text] [Related]
13. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
Yoshikawa H; Kiuchi T; Saida T; Takamori M
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):970-7. PubMed ID: 21784757
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
16. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
[TBL] [Abstract][Full Text] [Related]
17. Clinical study of FK506 in patients with myasthenia gravis.
Konishi T; Yoshiyama Y; Takamori M; Yagi K; Mukai E; Saida T;
Muscle Nerve; 2003 Nov; 28(5):570-4. PubMed ID: 14571458
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]